In Celexir’s body-recomposition toolkit, IGF-1 LR3 is positioned for hypertrophy support, cellular repair, and anabolic acceleration, often paired with GH-pathway secretagogues when the clinical goal is to add lean mass while protecting recovery capacity. It fits programs that also prioritize protein sufficiency, progressive resistance training, sleep, and inflammation control for durable results.
How it works: IGF-1 LR3 is an insulin-like growth factor analog engineered with an Arg3 substitution and extended N-terminus to reduce binding to IGF-binding proteins (IGFBPs) and prolong receptor-level signaling. Functionally, it stimulates myoblast proliferation/differentiation, increases protein synthesis, and improves nutrient partitioning, amplifying training-driven hypertrophy.
Evidence & diligence: Human, randomized data specific to LR3 are limited; clinical IGF-1 approvals are narrow (e.g., severe primary IGF-1 deficiency), and extrapolation to physique or rehab contexts remains investigational. Counsel on class-consistent risks (e.g., hypoglycemia, edema) and athletic restrictions—IGF-1 and analogues are prohibited by WADA—and monitor objective outcomes (strength, lean mass, function, fasting glucose/IGF-1).
Celexir delivery & specs: typical catalog guidance 20–100 mcg/day, cyclically; >98% purity (mass-spec tested); 2–8 °C storage; prefilled pen or lyophilized vial with CoA/handling docs for clean, repeatable workflows from warehouse to administration. Integrate LR3 as a supervised adjunct inside comprehensive programs and verify benefit with plan-level KPIs (strength, body-comp, recovery).